West China Medical of Sichuan University located in Chengdu, Sichuan, China has commissioned IBA to install a particle accelerator to produce radioisotopes for cancer diagnosis
November 25, 2020 – IBA (Louvain-la-Neuve, Belgium), the world’s leading provider of solutions for the diagnosis and treatment of cancer, and West China Medical center, the largest single-site hospital in the world consistently ranked in the top three hospitals in China, announce today that they have signed a contract for the installation of a 18 MeV cyclotron.
The Cyclone® KIUBE is a cyclotron used to produce radiopharmaceuticals dedicated to Positron emission tomography (PET), a modern cancer diagnostic method.
“PET imaging procedures play a critical role in medical care today and growing demand for radioisotopes in China means a greater need for efficiency.” Said Mr. Chen Li, Sales Director of IBA RadioPharma Solutions China. “The Cyclone KIUBE is more compact and powerful. It was developed with three keywords in mind, Reliability, High Performance and Flexibility.”
Bruno Scutnaire, President of IBA’s RadioPharma Solutions Business line said: “We are pleased that West China Medical Center has selected our Cyclone® KIUBE. For over 35 years, IBA has installed more than 600 particle accelerators worldwide, proving the excellent reliability of our systems.”
The Cyclone® KIUBE is Upgradable like no other cyclotron, West China Medical Center will be able to increase its production capacity step-by-step over time if needed, to reach up to 300 µA on target. The cyclotron will be ready for production of Ga-68, Cu-64 and Cu-61 with the IBA Nirta® liquid target.
IBA (Ion Beam Applications) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com